Aktienanalyse zu Immix Biopharma Inc (IMMX)IMMXImmix Biopharma Inc

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Immix Biopharma Inc is a good buy right now, trading at $13.94 with a strong analyst price target of $27 from Bank of America, suggesting a potential upside of about 93%. Additionally, the stock has shown impressive performance with a year-to-date change of +156.72% and a 1-year change of +511.40%. The main risk is the negative net income, which has been consistently high, with the latest quarter reporting a net loss of $11,557,002.